Lilly(LLY)2024-06-04 17:33Key Points Industry/Company Involved: * Eli Lilly and Company (NYSE:LLY) * Lilly Oncology Core Points and Arguments: 1. Oncology Strategy and Portfolio Modernization: Lilly has been working to modernize its oncology portfolio and strategy over the past couple of years. This includes a focus on biology, target selection, and building the right medicines. [5] 2. Acquisition of Loxo: Lilly acquired Loxo in 2019, bringing in a new team and a new approach to oncology drug development. [7] 3. Pipeline and Pipeline Efficiency: Lilly has terminated nearly the entire pipeline and started from scratch, focusing on building a pipeline with a higher probability of delivering successful medicines. [14] 4. Diversification of Modalities: Lilly has diversified its drug development approach, including small molecules, antibody drug conjugates, T-cell redirectors, and radioligand therapies. [16] 5. Clinical Trial Enrollment Bottleneck: Clinical trial enrollment remains a significant bottleneck in drug development. Lilly has initiated efforts to improve clinical trial access for patients. [23] 6. Commercial Performance: Lilly's oncology portfolio has seen robust growth, particularly with key growth brands like Verzenio, Retevmo, and Jaypirca. [19] 7. Investigational Portfolio: Lilly has a strong investigational portfolio, including new molecules and combinations targeting various cancer types. [24] 8. Precision Medicine: Lilly is focused on bringing precision medicine to larger populations, making a bigger impact on cancer care. [86] Other Important Points: 1. KRAS G12C Inhibitors: Lilly has a strong KRAS G12C inhibitor program, including olomorasib, targeting first-line lung cancer. [54] 2. Jaypirca: Jaypirca, a Bruton's tyrosine kinase inhibitor, has been approved for relapsed mantle cell lymphoma and CLL. [43] 3. LOXO-435: LOXO-435, an isoform-selective FGFR3 inhibitor, is being developed for metastatic urothelial cancer. [64] 4. Nectin-4 Targeted ADCs: Nectin-4 targeted ADCs are being developed for metastatic urothelial cancer. [64] 5. SMARCA2 Selective Inhibitor: A selective SMARCA2 selective inhibitor program is being developed in collaboration with Foghorn Therapeutics. [75] 6. Radioligand Therapy: Lilly has entered the radioligand therapy space with the acquisition of POINT Biopharma and partnerships with Aktis Oncology. [79] Data and Percentages: * 60% of eligible patients with high-risk early breast cancer are receiving Verzenio. [20] * 15% of breast cancer cases have H1047R mutations. [39] * 15-20% of patients with advanced urothelial cancer have FGFR alterations. [65] * 10% of lung cancer cases have SMARCA4 mutations. [75]